Physician profile
Virendra Joshi
NPI 1295828507
$16,041.88
in general payments reported to CMS, 2019-2025
21 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,382 · 2021: $1,440 · 2022: $746 · 2023: $4,263 · 2024: $1,036 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,815 · Food and Beverage: $1,635 · Education: $23.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,815.00 |
| Food and Beverage | $1,635.20 |
| Education | $23.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $6,228.96 | 2019 | |
| Ferring Pharmaceuticals INC. | $3,846.68 | 2023-2024 | Rebyota |
| Pentax of America, INC. | $2,209.68 | 2019-2024 | Pentax Medical, C2 Cryoballoon, Inspira |
| Merit Medical Systems INC | $1,677.85 | 2019 | |
| Cook Medical LLC | $501.16 | 2019-2025 | Hemospray, Echotip |
| Boston Scientific Corporation | $309.34 | 2022-2024 | |
| Mauna Kea Technologies, INC. | $241.14 | 2019-2022 | |
| Abbvie INC. | $199.47 | 2019-2024 | |
| Celgene Corporation | $139.96 | 2023-2024 | Zeposia |
| Medtronic, INC. | $120.97 | 2021 | |
| Fresenius Kabi USA, LLC | $116.55 | 2023-2024 | Idacio |
| Takeda Pharmaceuticals U.S.A., INC. | $111.09 | 2024 | |
| Olympus America INC. | $93.65 | 2024 | Single Use Biliary Balloon Dilator |
| Phathom Pharmaceuticals, INC. | $58.46 | 2023-2024 | Voquezna |
| Celltrion USA INC. | $54.63 | 2023-2024 | Vegzelma, Yuflyma |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $47.05 | 2023-2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $33.98 | 2024 | Dupixent |
| Biocon Biologics INC | $18.47 | 2024 | Hulio |
| Gilead Sciences, INC. | $18.29 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.50 | 2024 | Relistor |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virendra Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.